Penalty Amount
$7,400,000,000
Texas Attorney General Ken Paxton announced the effective date of a $7.4 billion settlement with Purdue Pharma, Inc. and the Sackler family over their role in fueling the opioid crisis. Texas will receive $286.5 million from the settlement, bringing the state’s total opioid recovery funds to over $3 billion. The settlement includes permanent bans on Sackler opioid sales in the U.S., public release of 30 million company documents, and distribution of funds for addiction treatment and prevention over 15 years.
The $7.4 billion settlement requires Purdue and the Sacklers to pay out funds over several years, with Texas receiving $286.5 million. The Sackler family is permanently barred from selling opioids in the United States. Purdue’s manufacturing operations are transferred to Knoa Pharma LLC, which is prohibited from marketing opioids and overseen by an independent monitor to prevent prescription opioid diversion. Over 30 million documents related to Purdue’s opioid business will be made public, and settlement funds will be distributed to states, communities, and individual victims over 15 years for addiction treatment, prevention, and recovery programs.
This enforcement action pertains to opioid manufacturing and marketing violations, with no privacy or data protection components. As such, there are no privacy-related contract clauses (e.g., data processing, breach notification, consent) that require review based on this action. In-house teams should instead refer to opioid-related regulations for relevant contract reviews, which are outside the scope of this privacy-focused extraction.
Entity
Purdue Pharma, Inc. and the Sackler Family
Industry
Healthcare"Purdue Pharma, Inc. (“Purdue”) and its owners, the Sackler family"
"a $7.4 billion settlement with Purdue Pharma, Inc. (“Purdue”) and its owners, the Sackler family"
"Texas is expected to receive $286.5 million from the settlement"
"settlement"
"Attorney General Ken Paxton"
"coalition of 55 states and territories"
$3.0M
Texas Attorney General Ken Paxton announced a settlement requiring Temu to protect Texans’ sensitive personal data from exposure to the Chinese Communist Party and to strengthen product-safety practices. Temu must pay Texas $3 million, comply with data-security requirements backed by a potential $8 million annual penalty, conduct annual independent product testing, and take specified action on products found to contain harmful substances.
$773.0M
Texas Attorney General Ken Paxton announced that a multistate coalition had secured an opioid settlement with Albertsons, which would require the grocery chain to pay more than $773 million nationally once final. Texas and its political subdivisions may receive up to $57.8 million for opioid abatement; the release does not identify privacy violations.
Texas Attorney General Ken Paxton sued Gerber Products Company and Nestlé USA, Inc., alleging that Gerber made deceptive safety and testing claims while its baby food contained dangerous levels of toxic heavy metals. The lawsuit asserts claims under the Texas Deceptive Trade Practices Act; the release does not report a settlement, monetary penalty, or court order.
$1.5M
The Texas Attorney General obtained a judgment holding Rubinsky Roofing LLC liable for 27 violations of the Texas Deceptive Trade Practices Act, including deceptive practices involving older consumers and payment for unnecessary or unfinished repairs. The judgment requires more than $1.5 million in civil penalties, allocates at least $500,000 to consumer restitution, and permanently bars the company and its owner from the practices at issue.
The Texas Attorney General opened an investigation into UnitedHealth Group over allegations that its insurance-benefit administration and patient-care decisions denied Texans medically necessary healthcare. The AG issued Civil Investigative Demands to collect evidence; the release announces no penalty or remedy.
$7.5M
Texas Attorney General Ken Paxton announced a $7.5 million settlement with Tris Pharmaceuticals over alleged misrepresentations about the efficacy of Dyanavel XR, an ADHD drug marketed for children. The release says the company overstated the drug’s efficacy and directed sales representatives to make misleading claims to doctors, including Medicaid providers.